21,130,400 Units INOVIO PHARMACEUTICALS, INC. PLACEMENT AGENT AGREEMENT
Exhibit 1.1
21,130,400 Units
January 24, 2011
▇▇▇▇ Capital Partners, LLC
▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Dear Sirs:
1. INTRODUCTION. Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
proposes to issue and sell to the purchasers, pursuant to the terms and conditions of this
Placement Agent Agreement (this “Agreement”) and the Subscription Agreements in the form of
Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers
identified therein (each a “Purchaser” and collectively, the “Purchasers”), up to an aggregate of
21,130,400 units (the “Units”) with each Unit consisting of (i) one share of common stock, $0.001
par value per share (the “Common Stock”) of the Company and (ii) one warrant to purchase 0.5 of one
share of Common Stock (a “Warrant” and, collectively, the “Warrants”). The terms and conditions of
the Warrants are set forth in the form of Exhibit B attached hereto. The Units will not be
issued or certificated. The Shares and Warrants are immediately separable and will be issued
separately. The Company hereby confirms its agreement with ▇▇▇▇ Capital Partners, LLC (the
“Placement Agent”) to act as Placement Agent in accordance with the terms and conditions hereof.
2. AGREEMENT TO ACT AS PLACEMENT AGENT; PLACEMENT OF SECURITIES. On the basis of the
representations, warranties and agreements of the Company herein contained, and subject to all the
terms and conditions of this Agreement:
(a) The Company hereby authorizes the Placement Agent to act as its exclusive agent to
solicit offers for the purchase of all or part of the Units from the Company in connection with
the proposed offering of the Units (the “Offering”). Until the Closing Date (as defined in
Section 4 hereof) or earlier upon termination of this Agreement pursuant to Section
9 the Company shall not, without the prior written consent of the Placement Agent, solicit
or accept offers to purchase Units otherwise than through the Placement Agent.
(b) The Company hereby acknowledges that the Placement Agent has agreed, as agent of the
Company, to use its best efforts to solicit offers to purchase the Units from the Company on the
terms and subject to the conditions set forth in the Prospectus (as defined below). The
Placement Agent shall use commercially reasonable efforts to assist the Company in obtaining
performance by each Purchaser whose offer to purchase Units has been solicited by the Placement
Agent and accepted by the Company, but the Placement Agent shall not, except as otherwise
provided in this Agreement, be obligated to disclose the identity of any potential purchaser or
have any liability to the Company in the event any such purchase is not consummated for any
reason. Under no circumstances will the Placement
Agent be obligated to underwrite or purchase any Units for its own account and, in
soliciting purchases of Units, the Placement Agent shall act solely as the Company’s agent and
not as principal.
(c) Subject to the provisions of this Section 2, offers for the purchase of Units
may be solicited by the Placement Agent as agent for the Company at such times and in such
amounts as the Placement Agent deems advisable. The Placement Agent shall communicate to the
Company, orally or in writing, each reasonable offer to purchase Units received by it as agent
of the Company. The Company shall have the sole right to accept offers to purchase the Units
and may reject any such offer, in whole or in part. The Placement Agent shall have the right,
in its discretion reasonably exercised, without notice to the Company, to reject any offer to
purchase Units received by it, in whole or in part, and any such rejection shall not be deemed a
breach of this Agreement.
(d) The Units are being sold to the Purchasers at a price of $1.15 per Unit. The purchases
of the Units by the Purchasers shall be evidenced by the execution of Subscription Agreements by
each of the Purchasers and the Company.
(e) As compensation for services rendered, on the Closing Date (as defined in Section
4 hereof), the Company shall pay to the Placement Agent by wire transfer of immediately
available funds to an account or accounts designated by the Placement Agent, an aggregate amount
equal to five percent (5.0%) of the gross proceeds received by the Company (the “Placement Fee”)
from the sale of the Units on such Closing Date.
(f) No Units which the Company has agreed to sell pursuant to this Agreement and the
Subscription Agreements shall be deemed to have been purchased and paid for, or sold by the
Company, until such Units shall have been delivered to the Purchaser thereof against payment by
such Purchaser. If the Company shall default in its obligations to deliver Units to a Purchaser
whose offer it has accepted, the Company shall indemnify and hold the Placement Agent harmless
against any loss, claim, damage or expense arising from or as a result of such default by the
Company in accordance with the procedures set forth in Section 8(c) herein.
3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to, and
agrees with, the Placement Agent and the Purchasers that:
(a) The Company has prepared and filed in conformity with the requirements of the
Securities Act of 1933, as amended (the “Securities Act”), and published rules and regulations
thereunder (the “Rules and Regulations”) adopted by the Securities and Exchange Commission (the
“Commission”), a “shelf Registration Statement (as hereinafter defined) on Form S-3 (File No.
333-160123), which became effective as of July 1, 2009 (the “Effective Date”), including a base
prospectus relating to the securities registered pursuant to such Registration Statement (the
“Base Prospectus”), and such amendments and supplements thereto as may have been required to the
date of this Agreement. The term “Registration Statement” as used in this Agreement means the
registration statement (including all exhibits, financial schedules and all documents and
information deemed to be a part of the Registration Statement pursuant to Rule 430A under the
Rules and Regulations),
-2-
as amended and/or supplemented to the date of this Agreement, including the Base
Prospectus. The Registration Statement is effective under the Securities Act and no stop order
preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the Commission and no proceedings for
that purpose have been instituted or, to the knowledge of the Company, are threatened by the
Commission. The Company, if required by the Rules and Regulations of the Commission, will file
the Prospectus (as defined below), with the Commission pursuant to Rule 424(b) under the Rules
and Regulations. The term “Prospectus,” as used in this Agreement means the Prospectus, in the
form in which it is to be filed with the Commission pursuant to Rule 424(b) under the Rules and
Regulations, or, if the Prospectus is not to be filed with the Commission pursuant to Rule
424(b), the Prospectus in the form included as part of the Registration Statement as of the
Effective Date, except that if any revised prospectus or prospectus supplement shall be provided
to the Placement Agent by the Company for use in connection with the offering and sale of the
Units which differs from the Prospectus (whether or not such revised prospectus or prospectus
supplement is required to be filed by the Company pursuant to Rule 424(b) under the Rules and
Regulations), the term “Prospectus” shall refer to such revised prospectus or prospectus
supplement, as the case may be, from and after the time it is first provided to the Placement
Agent for such use. Any preliminary prospectus or prospectus subject to completion included in
the Registration Statement or filed with the Commission pursuant to Rule 424 under the Rules and
Regulations is hereafter called a “Preliminary Prospectus.” Any reference herein to the
Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to
and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3
which were filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on
or before the last to occur of the Effective Date, the date of the Preliminary Prospectus, or
the date of the Prospectus, and any reference herein to the terms “amend,” “amendment,” or
“supplement” with respect to the Registration Statement, any Preliminary Prospectus or the
Prospectus shall be deemed to refer to and include (i) the filing of any document under the
Exchange Act after the Effective Date, the date of such Preliminary Prospectus or the date of
the Prospectus, as the case may be, which is incorporated by reference and (ii) any such
document so filed. If the Company has filed an abbreviated registration statement to register
additional securities pursuant to Rule 462(b) under the Rules (the “462(b) Registration
Statement”), then any reference herein to the Registration Statement shall also be deemed to
include such 462(b) Registration Statement.
(b) As of the Applicable Time (as defined below) and as of the Closing Date, neither (i)
any General Use Free Writing Prospectus (as defined below) issued at or prior to the Applicable
Time, and the Pricing Prospectus (as defined below) and the information included on Schedule
A hereto, all considered together (collectively, the “General Disclosure Package”), (ii) any
individual Limited Use Free Writing Prospectus (as defined below), nor (iii) the bona fide
electronic road show (as defined in Rule 433(h)(5) under the Rules and Regulations), if any,
that has been made available without restriction to any person, when considered together with
the General Disclosure Package, included or will include, any untrue statement of a material
fact or omitted or as of the Closing Date will omit, to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made,
not misleading; provided, however, that the Company makes no representations or warranties as to
information contained in or omitted
-3-
from any Issuer Free Writing Prospectus, in reliance upon, and in conformity with, written
information furnished to the Company by the Placement Agent specifically for inclusion therein,
which information the parties hereto agree is limited to the Placement Agent’s Information (as
defined in Section 17). As used in this paragraph (b) and elsewhere in this
Agreement:
“Applicable Time” means 6:00 A.M., New York time, on the date of this Agreement.
“General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is
identified on Schedule A to this Agreement.
“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule
433 under the Rules and Regulations relating to the Units in the form filed or required to be
filed with the Commission or, if not required to be filed, in the form retained in the Company’s
records pursuant to Rule 433(g) under the Rules and Regulations.
“Limited Use Free Writing Prospectuses” means any Issuer Free Writing Prospectus that is not a
General Use Free Writing Prospectus.
“Pricing Prospectus” means the Preliminary Prospectus, if any, and the Base Prospectus, each as
amended and supplemented immediately prior to the Applicable Time, including any document
incorporated by reference therein and any prospectus supplement deemed to be a part thereof.
(c) No order preventing or suspending the use of any Preliminary Prospectus, any Issuer
Free Writing Prospectus or the Prospectus relating to the Offering has been issued by the
Commission, and no proceeding for that purpose or pursuant to Section 8A of the Securities Act
has been instituted or threatened by the Commission, and each Preliminary Prospectus (if any),
at the time of filing thereof, conformed in all material respects to the requirements of the
Securities Act and the Rules and Regulations, and did not contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein, in the light of the circumstances under which they were made, not
misleading; provided, however, that the Company makes no representations or warranties as to
information contained in or omitted from any Preliminary Prospectus, in reliance upon, and in
conformity with, written information furnished to the Company by the Placement Agent
specifically for inclusion therein, which information the parties hereto agree is limited to the
Placement Agent’s Information (as defined in Section 17).
(d) At the time the Registration Statement became or becomes effective, at the date of this
Agreement and at the Closing Date, the Registration Statement conformed and will conform in all
material respects to the requirements of the Securities Act and the Rules and Regulations and
did not and will not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not
misleading; the Prospectus, at the time the Prospectus was issued and at the Closing Date,
conformed and will conform in all material respects to the requirements of the Securities Act
and the Rules and Regulations and did not and will not contain an untrue
-4-
statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in light of the circumstances under which they were made, not
misleading; provided, however, that the foregoing representations and warranties in this
paragraph (d) shall not apply to information contained in or omitted from the
Registration Statement or the Prospectus in reliance upon, and in conformity with, written
information furnished to the Company by the Placement Agent specifically for inclusion therein,
which information the parties hereto agree is limited to the Placement Agent’s Information (as
defined in Section 17).
(e) Each Issuer Free Writing Prospectus, if any, as of its issue date and at all subsequent
times through the completion of the public offer and sale of the Units or until any earlier date
that the Company notified or notifies the Placement Agent as described in Section 5(e),
did not, does not and will not include any information that conflicted, conflicts or will
conflict with the information contained in the Registration Statement, Pricing Prospectus or the
Prospectus, including any document incorporated by reference therein and any prospectus
supplement deemed to be a part thereof that has not been superseded or modified, or includes an
untrue statement of a material fact or omitted or would omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances prevailing at the subsequent time, not misleading. The foregoing sentence does
not apply to statements in or omissions from any Issuer Free Writing Prospectus in reliance
upon, and in conformity with, written information furnished to the Company by the Placement
Agent specifically for inclusion therein, which information the parties hereto agree is limited
to the Placement Agent’s Information (as defined in Section 17).
(f) The documents incorporated by reference in the Prospectus, when they became effective
or were filed with the Commission, as the case may be, conformed in all material respects to the
requirements of the Securities Act or the Exchange Act, as applicable, and the rules and
regulations of the Commission thereunder and none of such documents contained any untrue
statement of a material fact or omitted to state any material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading; and any further documents so filed and incorporated by reference in the
Prospectus, when such documents become effective or are filed with the Commission, as the case
may be, will conform in all material respects to the requirements of the Securities Act or the
Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and will
not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading.
(g) The Company has not, directly or indirectly, distributed and will not distribute any
offering material in connection with the Offering other than any Pricing Prospectus, the
Prospectus and other materials, if any, permitted under the Securities Act and consistent with
Section 5(b) below. The Company is not an “ineligible issuer” in connection with the offering
pursuant to Rules 164, 405 and 433 under the Securities Act. The Company will file with the
Commission all Issuer Free Writing Prospectuses (other than a “road show,” as
-5-
defined in Rule 433(d)(8) under the Rules and Regulations), if any, in the time and manner
required under Rules 163(b)(2) and 433(d) under the Rules and Regulations.
(h) The Company and each Subsidiary (as defined below) has been duly organized and is
validly existing as a corporation in good standing (or the foreign equivalent thereof) under the
laws of each of their respective jurisdictions of organization. The Company and each Subsidiary
is duly qualified to do business and is in good standing as a foreign corporation in each
jurisdiction in which its ownership or lease of property or the conduct of its business requires
such qualification and has all power and authority necessary to own or hold its properties and
to conduct the business in which it is engaged, except where the failure to so qualify or have
such power or authority (i) would not have, singularly or in the aggregate, a material adverse
effect on the condition (financial or otherwise), results of operations, assets or business or
prospects of the Company or any Subsidiary, taken as a whole, or (ii) impair in any material
respect the ability of the Company to perform its obligations under this Agreement or to
consummate any transactions contemplated by the Agreement, the General Disclosure Package or the
Prospectus (any such effect as described in clauses (i) or (ii), a “Material Adverse Effect”).
The Company owns or controls, directly or indirectly, only the following corporations,
partnerships, limited liability partnerships, limited liability companies, associations or other
entities: Genetronics, Inc., VGX Pharmaceuticals, LLC, VGX Animal Health, Inc. and Inovio Asia
Pte. Ltd. (each, a “Subsidiary” and, collectively, the “Subsidiaries”).
(i) The Company has the full right, power and authority to enter into this Agreement, the
Warrants and each of the Subscription Agreements and to perform and to discharge its obligations
hereunder and thereunder; and each of this Agreement, the Warrants and each of the Subscription
Agreements have been duly authorized, executed and delivered by the Company, and constitutes a
valid and binding obligation of the Company enforceable in accordance with its terms, except as
may be limited by bankruptcy, insolvency, reorganization or other similar laws affecting the
enforcement of creditors’ rights generally and by general principles of equity.
(j) The shares of Common Stock and Warrants to be issued and sold by the Company to the
Purchasers hereunder and under the Subscription Agreements and the shares of Common Stock
issuable upon the exercise of the Warrants (the “Warrant Shares”) have been duly authorized and
the Common Stock, when issued and delivered against payment therefor as provided herein and in
the Subscription Agreements and the Warrant Shares, when issued and delivered against payment
therefore as provided in the Warrants, will be validly issued, fully paid and non-assessable and
free of any preemptive or similar rights and will conform to the description thereof contained
in the General Disclosure Package and the Prospectus.
(k) The Company has an authorized capitalization as set forth in the Pricing Prospectus,
and all of the issued shares of capital stock of the Company have been duly authorized and
validly issued, are fully paid and non-assessable, have been issued in all material respects in
compliance with United States federal and state securities laws, and conform to the description
thereof contained in the General Disclosure Package and the Prospectus. As of September 30,
2010, there were 103,466,542 shares of Common Stock
-6-
issued and outstanding, 26 shares of Preferred Stock, par value $0.001 of the Company,
issued and outstanding and 23,997,001 shares of Common Stock were issuable upon the exercise of
all options, warrants and convertible securities outstanding as of such date. Since such date,
the Company has not issued any securities, other than Common Stock of the Company issued
pursuant to the exercise of stock options previously outstanding under the Company’s stock
option plans or the issuance of restricted Common Stock pursuant to employee stock purchase
plans. All of the Company’s options, warrants and other rights to purchase or exchange any
securities for shares of the Company’s capital stock have been duly authorized and validly
issued and were issued in all material respects in compliance with United States federal and
state securities laws. None of the outstanding shares of Common Stock was issued in violation
of any preemptive rights, rights of first refusal or other similar rights to subscribe for or
purchase securities of the Company. There are no authorized or outstanding shares of capital
stock, options, warrants, preemptive rights, rights of first refusal or other rights to
purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any
capital stock of the Company or any of its subsidiaries other than those described above or
accurately described in the General Disclosure Package. The description of the Company’s stock
option, stock bonus and other stock plans or arrangements, and the options or other rights
granted thereunder, as described in the General Disclosure Package and the Prospectus,
accurately and fairly present the information required to be shown with respect to such plans,
arrangements, options and rights.
(l) All the outstanding shares of capital stock of each Subsidiary have been duly
authorized and validly issued, are fully paid and non-assessable and, except to the extent set
forth in the General Disclosure Package or the Prospectus, are owned by the Company directly or
indirectly through one or more wholly-owned subsidiaries, free and clear of any claim, lien,
encumbrance, security interest, restriction upon voting or transfer or any other claim of any
third party.
(m) The execution, delivery and performance of this Agreement, the Subscription Agreements
and the Warrants by the Company, the issue and sale of the Units by the Company and the
consummation of the transactions contemplated hereby and thereby will not (with or without
notice or lapse of time or both) (i) conflict with or result in a breach or violation of any of
the terms or provisions of, constitute a default or Debt Repayment Triggering Event (as defined
below) under, give rise to any right of termination or other right or the cancellation or
acceleration of any right or obligation or loss of a benefit under, or give rise to the creation
or imposition of any lien, encumbrance, security interest, claim or charge upon any property or
assets of the Company or any Subsidiary pursuant to, any indenture, mortgage, deed of trust,
loan agreement or other agreement or instrument to which the Company or any Subsidiary is a
party or by which the Company or any Subsidiary is bound or to which any of the property or
assets of the Company or any Subsidiary is subject; (ii) result in any violation of the
provisions of the charter or by-laws (or analogous governing instruments, as applicable) of the
Company or any Subsidiary; or, (iii) to the Company’s knowledge, result in the violation of any
law, statute, rule, regulation, judgment, order or decree of any court or governmental agency or
body, domestic or foreign, having jurisdiction over the Company or any Subsidiary or any of
their properties or assets, except with respect to clauses (i) and (iii), any breaches,
violations or defaults which, singularly or in the aggregate, would not have a Material Adverse
Effect. A “Debt Repayment Triggering
-7-
Event” means any event or condition that gives, or with the giving of notice or lapse of
time would give the holder of any note, debenture or other evidence of indebtedness (or any
person acting on such holder’s behalf) the right to require the repurchase, redemption or
repayment of all or a portion of such indebtedness by the Company or any Subsidiary.
(n) Except for the registration of the securities offered in the Offering under the
Securities Act and such consents, approvals, authorizations, registrations or qualifications as
may be required under the Exchange Act and applicable state or foreign securities laws, the
Financial Industry Regulatory Authority (“FINRA”) and the NYSE Amex (“NYSE Amex”) in connection
with the offering and sale of the Units by the Company, no consent, approval, authorization or
order of, or filing, qualification or registration with, any court or governmental agency or
body, foreign or domestic, which has not been made, obtained or taken and is not in full force
and effect, is required for the execution, delivery and performance of this Agreement, the
Subscription Agreements and the Warrants by the Company, the offer or sale of the Units or the
consummation of the transactions contemplated hereby or thereby.
(o) Ernst & Young LLP, who have certified certain financial statements and related
schedules included or incorporated by reference in the Registration Statement, the General
Disclosure Package and the Prospectus, is an independent registered public accounting firm as
required by the Securities Act and the Rules and Regulations and the Public Company Accounting
Oversight Board (United States) (the “PCAOB”). Except as pre-approved in accordance with the
requirements set forth in Section 10A of the Exchange Act, Ernst & Young LLP has not been
engaged by the Company to perform any “prohibited activities” (as defined in Section 10A of the
Exchange Act).
(p) The financial statements, together with the related notes and schedules, included or
incorporated by reference in the General Disclosure Package, the Prospectus and in the
Registration Statement fairly present in all material respects the financial position and the
results of operations and changes in financial position of the Company and its consolidated
subsidiaries and other consolidated entities at the respective dates or for the respective
periods therein specified. Such statements and related notes and schedules have been prepared
in accordance with the generally accepted accounting principles in the United States (“GAAP”)
applied on a consistent basis throughout the periods involved except as may be set forth in the
related notes included or incorporated by reference in the General Disclosure Package. The
financial statements, together with the related notes and schedules, included or incorporated by
reference in the General Disclosure Package and the Prospectus comply in all material respects
with the Securities Act, the Exchange Act, and the Rules and Regulations and the rules and
regulations under the Exchange Act. No other financial statements or supporting schedules or
exhibits are required by the Securities Act or the Rules and Regulations to be described, or
included or incorporated by reference in the Registration Statement, the General Disclosure
Package or the Prospectus. There is no pro forma or as adjusted financial information which is
required to be included in the Registration Statement, the General Disclosure Package, or the
Prospectus or a document incorporated by reference therein in accordance with the Securities Act
and the Rules and Regulations which has not been included or incorporated as so required. The
pro forma and pro forma as adjusted financial information and the related notes included or
incorporated by reference in
-8-
the Registration Statement, the General Disclosure Package and the Prospectus have been
properly compiled and prepared in accordance with the applicable requirements of the Securities
Act and the Rules and Regulations and present fairly the information shown therein, and the
assumptions used in the preparation thereof are reasonable and the adjustments used therein are
appropriate to give effect to the transactions and circumstances referred to therein.
(q) Neither the Company nor any Subsidiary has sustained, since the date of the latest
audited financial statements included or incorporated by reference in the General Disclosure
Package, any material loss or interference with its business from fire, explosion, flood or
other calamity, whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, otherwise than as set forth or contemplated in the General
Disclosure Package; and, since such date, there has not been any change in the capital stock or
long-term debt of the Company or any Subsidiary or any material adverse changes, or any
development involving a prospective material adverse change, in or affecting the business,
assets, management, financial position, prospects, stockholders’ equity or results of operations
of the Company or any Subsidiary, otherwise than as set forth or contemplated in the General
Disclosure Package.
(r) Except as set forth in the General Disclosure Package, there is no legal or
governmental action, suit, claim or proceeding pending to which the Company or any Subsidiary is
a party or of which any property or assets of the Company or any Subsidiary is the subject which
is required to be described in the Registration Statement, the General Disclosure Package or the
Prospectus or a document incorporated by reference therein and is not described therein, or
which, singularly or in the aggregate, if determined adversely to the Company or any Subsidiary
could have a Material Adverse Effect or prevent the consummation of the transactions
contemplated hereby; and to the best of the Company’s knowledge, no such proceedings are
threatened or contemplated by governmental authorities or threatened by others.
(s) Neither the Company nor any Subsidiary is in (i) violation of its charter or by-laws
(or analogous governing instrument, as applicable), (ii) default in any respect, and no event
has occurred which, with notice or lapse of time or both, would constitute such a default, in
the due performance or observance of any term, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a
party or by which it is bound or to which any of its property or assets is subject or (iii) to
the Company’s knowledge, violation of any law, ordinance, governmental rule, regulation or court
order, decree or judgment to which it or its property or assets is subject except, in the case
of clauses (ii) and (iii) of this paragraph(s), for any violations or defaults which, singularly
or in the aggregate, would not have a Material Adverse Effect.
(t) The Company and each Subsidiary possesses all licenses, certificates, authorizations
and permits issued by, and have made all declarations and filings with, the appropriate local,
state, federal or foreign regulatory agencies or bodies which are necessary or desirable for the
ownership of its properties or the conduct of their respective businesses as described in the
General Disclosure Package and the Prospectus (collectively, the
-9-
“Governmental Permits”) except where any failures to possess or make the same, singularly
or in the aggregate, would not have a Material Adverse Effect. The Company and each Subsidiary
is in compliance with all such Governmental Permits, and all such Governmental Permits are valid
and in full force and effect, except where any non-compliance or the validity or failure to be
in full force and effect would not, singularly or in the aggregate, have a Material Adverse
Effect. To the Company’s knowledge, all such Governmental Permits are free and clear of any
restriction or condition that are in addition to, or materially different from those normally
applicable to similar licenses, certificates, authorizations and permits. Neither the Company
nor any Subsidiary has received notification of any revocation or modification (or proceedings
related thereto) of any such Governmental Permit and, to the Company’s knowledge, there is no
reason to believe that any such Governmental Permit will not be renewed.
(u) Neither the Company nor any Subsidiary is or, after giving effect to the offering of
the Units and the application of the proceeds thereof as described in the General Disclosure
Package and the Prospectus, will become an “investment company” within the meaning of the
Investment Company Act of 1940, as amended, and the rules and regulations of the Commission
thereunder.
(v) Neither the Company nor any Subsidiary, nor to the Company’s knowledge, any of the
Company’s and any Subsidiary’s officers, directors or affiliates has taken or will take,
directly or indirectly, any action designed or intended to stabilize or manipulate the price of
any security of the Company, or which caused or resulted in, or which might in the future
reasonably be expected to cause or result in, stabilization or manipulation of the price of any
security of the Company.
(w) To the best of the Company’s knowledge, the Company and each Subsidiary owns or
possesses the right to use all patents, trademarks, trademark registrations, service marks,
service ▇▇▇▇ registrations, trade names, copyrights, licenses, inventions, software, databases,
know-how, Internet domain names, trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures, and other intellectual property
(collectively, “Intellectual Property”) necessary to carry on their respective businesses as
currently conducted, and as proposed to be conducted and described in the General Disclosure
Package and the Prospectus, and the Company is not aware of any claim to the contrary or any
challenge by any other person to the rights of the Company or any Subsidiary with respect to the
foregoing except for those that could not have a Material Adverse Effect. The Intellectual
Property licenses described in the General Disclosure Package and the Prospectus are valid,
binding upon, and enforceable by or against the parties thereto in accordance to its terms. The
Company and each Subsidiary has complied in all material respects with, and is not in breach nor
has received any asserted or threatened claim of breach of, any Intellectual Property license,
and the Company has no knowledge of any breach or anticipated breach by any other person to any
Intellectual Property license. To the best of the Company’s knowledge, the Company’s and each
Subsidiary’s business as now conducted and as proposed to be conducted does not and will not
infringe or conflict with any valid patents, trademarks, service marks, trade names, copyrights,
trade secrets, licenses or other Intellectual Property or franchise right of any person, except
for any such acts that would not have a Material Adverse Effect. No claim
-10-
has been made against
the Company or
any Subsidiary alleging the infringement by the Company or any Subsidiary of any patent,
trademark, service ▇▇▇▇, trade name, copyright, trade secret, license in or other intellectual
property right or franchise right of any person. The Company and each Subsidiary has taken all
reasonable steps to protect, maintain and safeguard its rights in all Intellectual Property,
including the execution of appropriate nondisclosure and confidentiality agreements. The
consummation of the transactions contemplated by this Agreement will not result in the loss or
impairment of or payment of any additional amounts with respect to, nor require the consent of
any other person in respect of, each of the Company’s and each Subsidiary’s right to own, use,
or hold for use any of the Intellectual Property as owned, used or held for use in the conduct
of its business as currently conducted. The Company and each Subsidiary has at all times
complied in all material respects with all applicable laws relating to privacy, data protection,
and the collection and use of personal information collected, used, or held for use by the
Company or any Subsidiary in the conduct of the Company’s or any Subsidiary’s business. No
claims have been asserted or threatened against the Company or any Subsidiary alleging a
violation of any person’s privacy or personal information or data rights and the consummation of
the transactions contemplated hereby will not breach or otherwise cause any violation of any law
related to privacy, data protection, or the collection and use of personal information
collected, used, or held for use by the Company or any Subsidiary in the conduct of the
Company’s or any Subsidiary’s business. The Company and each Subsidiary takes reasonable
measures to ensure that such information is protected against unauthorized access, use,
modification, or other misuse.
(x) The Company and each Subsidiary has good and marketable title in fee simple to, or have
valid rights to lease or otherwise use, all items of real or personal property which are
material to the business of the Company and any Subsidiary, free and clear of all liens,
encumbrances, security interests, claims and defects that do not, singularly or in the
aggregate, materially affect the value of such property and do not interfere with the use made
and proposed to be made of such property by the Company or any Subsidiary; and all of the leases
and subleases material to the business of the Company or any Subsidiary, and under which the
Company or any Subsidiary holds properties described in the General Disclosure Package and the
Prospectus, are in full force and effect, and neither the Company nor any Subsidiary has
received any notice of any material claim of any sort that has been asserted by anyone adverse
to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned
above, or affecting or questioning the rights of the Company or any Subsidiary to the continued
possession of the leased or subleased premises under any such lease or sublease.
(y) No organized labor disturbance by the employees of the Company or any Subsidiary exists
or, to the best of the Company’s knowledge, is imminent, and the Company has no actual knowledge
of any existing or imminent labor disturbance by the employees of any of its or any Subsidiary’s
principal suppliers, manufacturers, customers or contractors, that could reasonably be expected,
singularly or in the aggregate, to have a Material Adverse Effect. The Company is not aware
that any key employee or significant group of employees of the Company or any Subsidiary plans
to terminate employment with the Company or any Subsidiary.
-11-
(z) No “prohibited transaction” (as defined in Section 406 of the Employee Retirement
Income Security Act of 1974, as amended, including the regulations and published interpretations
thereunder (“ERISA”), or Section 4975 of the Internal Revenue Code of 1986, as amended from time
to time (the “Code”)) or “accumulated funding deficiency” (as defined in Section 302 of ERISA)
or any of the events set forth in Section 4043(b) of ERISA (other than events with respect to
which the thirty (30)-day notice requirement under Section 4043 of ERISA has been waived) has
occurred or could reasonably be expected to occur with respect to any employee benefit plan of
the Company or any Subsidiary which could, singularly or in the aggregate, have a Material
Adverse Effect. Each employee benefit plan of the Company or any Subsidiary is in compliance in
all material respects with applicable law, including ERISA and the Code. The Company and each
Subsidiary has not incurred and could not reasonably be expected to incur liability under Title
IV of ERISA with respect to the termination of, or withdrawal from, any pension plan (as defined
in ERISA). Each pension plan for which the Company or any Subsidiary would have any liability
that is intended to be qualified under Section 401(a) of the Code is so qualified, and nothing
has occurred, whether by action or by failure to act, which could, singularly or in the
aggregate, cause the loss of such qualification to the extent such loss would have a Material
Adverse Effect.
(aa) To the best of the Company’s knowledge, the Company and each Subsidiary is in
compliance with all foreign, federal, state and local rules, laws and regulations relating to
the use, treatment, storage and disposal of hazardous or toxic substances or waste and
protection of health and safety or the environment which are applicable to its businesses
(“Environmental Laws”), except where the failure to comply would not, singularly or in the
aggregate, have a Material Adverse Effect. There has been no storage, generation,
transportation, handling, treatment, disposal, discharge, emission, or other release of any kind
of toxic or other wastes or other hazardous substances regulated by Environmental Laws
(“Hazardous Substances”) by or caused by the Company or any Subsidiary (or, to the Company’s
knowledge and without independent investigation, any other entity for whose acts or omissions
the Company or any Subsidiary is or may otherwise be liable) upon any of the property now or
previously owned or leased by the Company or any Subsidiary, or upon any other property, in
violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or
which would, under any law, statute, ordinance, rule (including rule of common law), regulation,
order, judgment, decree or permit, give rise to any liability, except for any violation or
liability which would not have, singularly or in the aggregate with all such violations and
liabilities, a Material Adverse Effect; to the Company’s actual knowledge and without
independent investigation, there has been no disposal, discharge, emission or other release onto
property now leased by the Company or any Subsidiary or into the environment surrounding such
property of any Hazardous Substance, except for any such disposal, discharge, emission, or other
release in violation of Environmental Laws which would not have, singularly or in the aggregate
with all such discharges and other releases, a Material Adverse Effect.
(bb) The Company and each Subsidiary (i) has timely filed (or filed an extension to file)
all necessary federal, state, local and foreign tax returns, and all such filed returns were
true, complete and correct, (ii) has paid all federal, state, local and foreign taxes,
assessments, governmental or other charges due and payable for which it is liable, including,
without
-12-
limitation, all sales and use taxes and all taxes which the Company or any Subsidiary is
obligated to withhold from amounts owing to employees, creditors and third parties, and (iii)
does not have any tax deficiency or claims outstanding or assessed or, to the best of its
knowledge, proposed against any of them, except those, in each of the cases described in clauses
(i), (ii) and (iii) of this paragraph (bb), that would not, singularly or in the
aggregate, have a Material Adverse Effect. The Company and each Subsidiary has not engaged in
any transaction which is a corporate tax shelter or which could be characterized as such by the
Internal Revenue Service or any other taxing authority. The accruals and reserves on the books
and records of the Company in respect of tax liabilities for any taxable period not yet finally
determined are adequate to meet any assessments and related liabilities for any such period, and
since December 31, 2008, the Company and each Subsidiary has not incurred any liability for
taxes other than in the ordinary course.
(cc) The Company and each Subsidiary carries, or is covered by, insurance provided by
recognized, financially sound and reputable institutions with policies in such amounts and
covering such risks as is adequate for the conduct of their respective businesses and the value
of its properties and as is customary for companies engaged in similar businesses in similar
industries. The Company has no reason to believe that it or any Subsidiary will not be able (i)
to renew its existing insurance coverage as and when such policies expire or (ii) to obtain
comparable coverage from similar institutions as may be necessary or appropriate to conduct
their respective businesses as now conducted and at a cost that would not result in a Material
Adverse Effect. Neither the Company nor any Subsidiary has been denied any insurance coverage
that it has sought or for which it has applied.
(dd) The Company and each Subsidiary maintains a system of internal accounting and other
controls sufficient to provide reasonable assurances that (i) transactions are executed in
accordance with management’s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to
maintain accountability for assets; (iii) access to assets is permitted only in accordance with
management’s general or specific authorization; and (iv) the recorded accountability for assets
is compared with existing assets at reasonable intervals and appropriate action is taken with
respect to any differences. Except as described in the General Disclosure Package, since the
end of the Company’s most recent audited fiscal year, there as been (A) no material weakness in
the Company’s internal control over financial reporting (whether or not remediated) and (B) no
change in the Company’s internal control over financial reporting that has materially affected,
or is reasonably likely to materially affect, the Company’s internal control over financial
reporting.
(ee) The minute books of the Company and each Subsidiary have been made available to the
Placement Agent and counsel for the Placement Agent, and such books (i) contain a complete
summary in all material respects of all meetings and actions of the board of directors
(including each board committee) and shareholders of the Company and each Subsidiary (or
analogous governing bodies and interest holders, as applicable), since February 1, 2007 through
the date of the latest meeting and action, and (ii) accurately, in all material respects,
reflect all transactions referred to in such minutes.
-13-
(ff) There is no franchise, lease, contract, agreement or document required by the
Securities Act or by the Rules and Regulations to be described in the General Disclosure Package
and in the Prospectus or a document incorporated by reference therein or to be filed as an
exhibit to the Registration Statement or a document incorporated by reference therein which is
not described or filed therein as required; and all descriptions of any such franchises, leases,
contracts, agreements or documents contained in the Registration Statement or in a document
incorporated by reference therein are accurate and complete descriptions of such documents in
all material respects. Other than as described in the General Disclosure Package, no such
franchise, lease, contract or agreement has been suspended or terminated for convenience or
default by the Company or any Subsidiary or any of the other parties thereto, and neither the
Company nor any Subsidiary has received notice nor does the Company have any other knowledge of
any such pending or threatened suspension or termination, except for such pending or threatened
suspensions or terminations that would not reasonably be expected to, singularly or in the
aggregate, have a Material Adverse Effect.
(gg) No relationship, direct or indirect, exists between or among the Company and any
Subsidiary on the one hand, and the directors, officers, stockholders (or analogous interest
holders), customers or suppliers of the Company or any Subsidiary or any of their affiliates on
the other hand, which is required to be described in the General Disclosure Package and the
Prospectus or a document incorporated by reference therein and which is not so described.
(hh) No person or entity has the right to require registration of shares of Common Stock or
other securities of the Company or any Subsidiary because of the filing or effectiveness of the
Registration Statement or otherwise, except for persons and entities who have expressly waived
such right in writing or who have been given timely and proper written notice and have failed to
exercise such right within the time or times required under the terms and conditions of such
right. Except as described in the General Disclosure Package, there are no persons with
registration rights or similar rights to have any securities registered by the Company or any
Subsidiary under the Securities Act.
(ii) Neither the Company nor any Subsidiary owns any “margin securities” as that term is
defined in Regulation U of the Board of Governors of the Federal Reserve System (the “Federal
Reserve Board”), and none of the proceeds of the sale of the Units will be used, directly or
indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of
reducing or retiring any indebtedness which was originally incurred to purchase or carry any
margin security or for any other purpose which might cause any of the Units to be considered a
“purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.
(jj) Except for this Agreement, neither the Company nor any Subsidiary is a party to any
contract, agreement or understanding with any person that would give rise to a valid claim
against the Company or the Placement Agent for a brokerage commission, finder’s fee or like
payment in connection with the offering and sale of the Units or any transaction contemplated by
this Agreement, the Registration Statement, the General Disclosure Package or the Prospectus.
-14-
(kk) No forward-looking statement (within the meaning of Section 27A of the Securities Act
and Section 21E of the Exchange Act) contained in either the General Disclosure Package or the
Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other
than in good faith.
(ll) The Company is subject to and in compliance in all material respects with the
reporting requirements of Section 13 or Section 15(d) of the Exchange Act. The Common Stock is
registered pursuant to Section 12(b) of the Exchange Act and is listed on the NYSE Amex, and the
Company has taken no action designed to, or reasonably likely to have the effect of, terminating
the registration of the Common Stock under the Exchange Act or delisting the Common Stock from
the NYSE Amex, nor has the Company received any notification that the Commission, the NYSE Amex
or FINRA is contemplating terminating such registration or listing. The Company has obtained or
will have obtained, or has made or will have made, as applicable, all necessary consents,
approvals, authorizations or orders of, or filing, notification or registration with, the NYSE
Amex is required for the listing and trading of the shares of Common Stock on the NYSE Amex.
(mm) The Company is in material compliance with all applicable provisions of the
▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act of 2002 and all rules and regulations promulgated thereunder or implementing
the provisions thereof (the “▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act”).
(nn) The Company is in material compliance with all applicable corporate governance
requirements set forth in the NYSE Amex Rules.
(oo) Neither the Company nor any Subsidiary, nor, to the best of the Company’s knowledge,
any employee or agent of the Company or any Subsidiary, has made any contribution or other
payment to any official of, or candidate for, any federal, state, local or foreign office in
violation of any law (including the Foreign Corrupt Practices Act of 1977, as amended) or of the
character required to be disclosed in the Registration Statement, the General Disclosure Package
or the Prospectus or a document incorporated by reference therein.
(pp) There are no transactions, arrangements or other relationships between and/or among
the Company or any Subsidiary, any of their affiliates (as such term is defined in Rule 405 of
the Securities Act) and any unconsolidated entity, including, but not limited to, any structured
finance, special purpose or limited purpose entity that could reasonably be expected to
materially affect the Company’s or any Subsidiary’s liquidity or the availability of or
requirements for their capital resources required to be described in the General Disclosure
Package and the Prospectus or a document incorporated by reference therein which have not been
described as required.
(qq) There are no outstanding loans, advances (except normal advances for business expenses
in the ordinary course of business) or guarantees or indebtedness by the Company to or for the
benefit of any of the officers or directors of the Company or any of their respective family
members, except as disclosed in the Registration Statement, the General Disclosure Package and
the Prospectus.
-15-
(rr) The statistical and market related data included in the Registration Statement, the
General Disclosure Package and the Prospectus are based on or derived from sources that the
Company believes to be reliable and accurate, and such data agree with the sources from which
they are derived.
(ss) The operations of the Company and each Subsidiary are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements of the
Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering
statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering
Laws”), and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any Subsidiary with respect to the
Money Laundering Laws is pending, or to the best knowledge of the Company, threatened.
(tt) Neither the Company nor any Subsidiary nor, to the knowledge of the Company, any
director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S.
Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds
of the offering, or lend, contribute or otherwise make available such proceeds to any
Subsidiary, joint venture partner or other person or entity, for the purpose of financing the
activities of any person currently subject to any U.S. sanctions administered by OFAC.
(uu) Neither the Company, nor any Subsidiary, nor any of their affiliates (within the
meaning of NASD Conduct Rule 2720(b)(1)(a)) directly or indirectly controls, is controlled by,
or is under common control with, or is an associated person (within the meaning of Article I,
Section l(ee) of the By-laws of FINRA) of, any member firm of FINRA.
(vv) No approval of the shareholders of the Company under the rules and regulations of NYSE
Amex (including Rule 713 of the NYSE Amex Rules) is required for the Company to issue and
deliver to the Purchasers the Units
(ww) All preclinical and clinical studies conducted by or on behalf of the Company or any
Subsidiary that are material to the Company and its Subsidiaries, taken as a whole, are
described in the General Disclosure Package or the Prospectus. To the Company’s knowledge,
after reasonable inquiry, the clinical and preclinical studies conducted by or on behalf of the
Company or any Subsidiary that are described in the General Disclosure Package or the Prospectus
or the results of which are referred to in the General Disclosure Package or the Prospectus were
and, if still ongoing, are being conducted in material compliance with all laws and regulations
applicable thereto in the jurisdictions in which they are being conducted and with all laws and
regulations applicable to preclinical and clinical studies from which data will be submitted to
support marketing approval. The descriptions in the General Disclosure Package or the Prospectus
of the results of such studies are accurate and complete in all material respects and fairly
present the data derived from such studies, and the Company has no knowledge of any large
well-controlled clinical study the aggregate results of which are inconsistent with or otherwise
call into question the results of any clinical study conducted by or on behalf of the Company or
any Subsidiary that are described
-16-
in the General Disclosure Package or the Prospectus or the results of which are referred to
in the General Disclosure Package or the Prospectus. Except as disclosed in the General
Disclosure Package or the Prospectus, the Company has not received any written notices or
statements from the United States Food and Drug Administration (the “FDA”), the European
Medicines Agency (“EMEA”) or any other governmental agency or authority imposing, requiring,
requesting or suggesting a clinical hold, termination, suspension or material modification for
or of any clinical or preclinical studies that are described in the General Disclosure Package
or the Prospectus or the results of which are referred to in the General Disclosure Package or
the Prospectus.
(xx) Except as disclosed in the General Disclosure Package or the Prospectus, the Company
has not received any written notices or statements from the FDA, the EMEA or any other
governmental agency, and otherwise has no knowledge or reason to believe, that (i) any new drug
application or marketing authorization application for any product or potential product of the
Company or any Subsidiary is or has been rejected or determined to be non-approvable or
conditionally approvable; (ii) a delay in time for review and/or approval of a marketing
authorization application or marketing approval application in any other jurisdiction for any
product or potential product of the Company or any Subsidiary is or may be required, requested
or being implemented; (iii) one or more clinical studies for any product or potential product of
the Company or any Subsidiary shall or may be requested or required in addition to the clinical
studies described in the General Disclosure Package or the Prospectus as a precondition to or
condition of issuance or maintenance of a marketing approval for such product or potential
product; (iv) any license, approval, permit or authorization to conduct any clinical trial of or
market any product or potential product of the Company or any Subsidiary has been, will be or
may be suspended, revoked, modified or limited, except in the cases of clauses (i), (ii), (iii)
and (iv) where such rejections, determinations, delays, requests, suspensions, revocations,
modifications or limitations would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect.
(yy) Except as disclosed in the General Disclosure Package or the Prospectus, to the
Company’s knowledge, the preclinical and clinical testing, application for marketing approval
of, manufacture, distribution, promotion and sale of the products and potential products of the
Company or any Subsidiary is in compliance, in all material respects, with all laws, rules and
regulations applicable to such activities, including without limitation applicable good
laboratory practices, good clinical practices and good manufacturing practices, except for such
non-compliance as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect. The descriptions of the results of such tests and trials contained in
the General Disclosure Package and the Prospectus are accurate in all material respects. Except
to the extent disclosed in the General Disclosure Package or the Prospectus, the Company has not
received notice of adverse finding, warning letter or clinical hold notice from the FDA or any
non-U.S. counterpart of any of the foregoing, or any untitled letter or other correspondence or
notice from the FDA or any other governmental authority or agency or any institutional or
ethical review board alleging or asserting noncompliance with any law, rule or regulation
applicable in any jurisdiction, except notices, letters, and correspondences and non-U.S.
counterparts thereof alleging or asserting such noncompliance as would not, individually or in
the aggregate, reasonably be
-17-
expected to have a Material Adverse Effect. Except as disclosed in the General Disclosure
Package or the Prospectus, neither the Company nor any Subsidiary has, either voluntarily or
involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued,
any recall, field correction, market withdrawal or replacement, safety alert, warning, “dear
doctor” letter, investigator notice, or other notice or action relating to an alleged or
potential lack of safety or efficacy of any product or potential product of the Company or any
Subsidiary, any alleged product defect of any product or potential product of the Company or any
Subsidiary, or any violation of any material applicable law, rule, regulation or any clinical
trial or marketing license, approval, permit or authorization for any product or potential
product of the Company or any Subsidiary, and the Company is not aware of any facts or
information that would cause it to initiate any such notice or action and has no knowledge or
reason to believe that the FDA, the EMEA or any other governmental agency or authority or any
institutional or ethical review board or other non-governmental authority intends to impose,
require, request or suggest such notice or action. The pre-clinical or clinical studies, tests,
investigations, and trials conducted by or on behalf of the Company or any Subsidiary that are
described in the General Disclosure Package were and, if still in progress, are being, conducted
in compliance with all applicable U.S. and foreign statutes, rules, regulations, orders, or
other laws, and, for any data to be submitted to the FDA pursuant to such studies, all
applicable Good Laboratory Practices and Good Clinical Practices in all material respects. The
descriptions of the pre-clinical or clinical studies, tests, investigations, and trials,
including the related results and regulatory status thereof, contained in the General Disclosure
Package and the Prospectus are accurate in all material respects. The Company has not received
and is otherwise not aware of any notices, correspondence or other communication from the FDA,
the EMEA or other governmental regulatory agency or subdivision thereof, or any institutional or
ethical review boards, asserting non-compliance with any applicable statutes, rules,
regulations, orders, or other laws, or requiring or requesting the termination, suspension or
modification of any preclinical or clinical studies, tests, investigations, or trials conducted
by, or on behalf of, the Company or any Subsidiary or in which the Company or any Subsidiary has
participated.
(zz) Any certificate signed by or on behalf of the Company and delivered to the Placement
Agent or to counsel for the Placement Agent shall be deemed to be a representation and warranty
by the Company to the Placement Agent and the Purchasers as to the matters covered thereby.
4. THE CLOSING. The time and date of closing and delivery of the documents required to be
delivered to the Placement Agent pursuant to Sections 5 and 7 hereof shall be at 11:00
A.M., New York time, on January 27, 2011 (the “Closing Date”) at the office of ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇,
P.C., ▇▇▇▇ ▇▇▇▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇.
5. FURTHER AGREEMENTS OF THE COMPANY. The Company agrees with the Placement Agent and the
Purchasers:
(a) To prepare the Rule 462(b) Registration Statement, if necessary, in a form approved by
the Placement Agent and file such Rule 462(b) Registration Statement with the Commission on the
date hereof; to prepare the Prospectus in a form approved by the Placement Agent containing
information previously omitted at the time of effectiveness of
-18-
the Registration Statement in reliance on rules 430A, 430B and 430C and to file such
Prospectus pursuant to Rule 424(b) under the Rules and Regulations not later than the second
(2nd)business day following the execution and delivery of this Agreement or, if
applicable, such earlier time as may be required by Rule 430A under the Rules and Regulations;
to notify the Placement Agent immediately of the Company’s intention to file or prepare any
supplement or amendment to any Registration Statement or to the Prospectus and to make no
amendment or supplement to the Registration Statement, the General Disclosure Package or to the
Prospectus to which the Placement Agent shall reasonably object by notice to the Company after a
reasonable period to review; to advise the Placement Agent, promptly after it receives notice
thereof, of the time when any amendment to any Registration Statement has been filed or becomes
effective or any supplement to the General Disclosure Package or the Prospectus or any amended
Prospectus has been filed and to furnish the Placement Agent copies thereof; to file promptly
all material required to be filed by the Company with the Commission pursuant to Rule 433(d) or
163(b)(2), as the case may be; to file promptly all reports and any definitive proxy or
information statements required to be filed by the Company with the Commission pursuant to
Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus
and for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in
Rule 173(a) under the Rules and Regulations) is required in connection with the offering or sale
of the Units; to advise the Placement Agent, promptly after it receives notice thereof, of the
issuance by the Commission of any stop order or of any order preventing or suspending the use of
any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus, of the
suspension of the qualification of the Units for offering or sale in any jurisdiction, of the
initiation or threatening of any proceeding for any such purpose, or of any request by the
Commission for the amending or supplementing of the Registration Statement, the General
Disclosure Package or the Prospectus or for additional information; and, in the event of the
issuance of any stop order or of any order preventing or suspending the use of any Preliminary
Prospectus, any Issuer Free Writing Prospectus or the Prospectus or suspending any such
qualification, and promptly to use its best efforts to obtain the withdrawal of such order.
(b) The Company represents and agrees that, unless it obtains the prior consent of the
Placement Agent, it has not made and will not, make any offer relating to the Units that would
constitute a “free writing prospectus” as defined in Rule 405 under the Rules and Regulations
unless the prior written consent of the Placement Agent has been received (each, a “Permitted
Free Writing Prospectus”); provided that the prior written consent of the Placement Agent hereto
shall be deemed to have been given in respect of the Issuer Free Writing Prospectus[es] included
in Schedule A hereto. The Company represents that it has treated and agrees that it
will treat each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, comply
with the requirements of Rules 164 and 433 under the Rules and Regulations applicable to any
Issuer Free Writing Prospectus, including the requirements relating to timely filing with the
Commission, legending and record keeping and will not take any action that would result in the
Placement Agent or the Company being required to file with the Commission pursuant to Rule
433(d) under the Rules and Regulations a free writing prospectus prepared by or on behalf of the
Placement Agent that the Placement Agent otherwise would not have been required to file
thereunder.
-19-
(c) If at any time when a Prospectus relating to the Units is required to be delivered
under the Securities Act, any event occurs or condition exists as a result of which the
Prospectus, as then amended or supplemented, would include any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading, or the Registration
Statement, as then amended or supplemented, would include any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein not misleading,
or if for any other reason it is necessary at any time to amend or supplement any Registration
Statement or the Prospectus to comply with the Securities Act or the Exchange Act, the Company
will promptly notify the Placement Agent, and upon the Placement Agent’s request, the Company
will promptly prepare and file with the Commission, at the Company’s expense, an amendment to
the Registration Statement or an amendment or supplement to the Prospectus that corrects such
statement or omission or effects such compliance and will deliver to the Placement Agent,
without charge, such number of copies thereof as the Placement Agent may reasonably request.
The Company consents to the use of the Prospectus or any amendment or supplement thereto by the
Placement Agent.
(d) If the General Disclosure Package is being used to solicit offers to buy the Units at a
time when the Prospectus is not yet available to prospective purchasers and any event shall
occur as a result of which, in the judgment of the Company or in the reasonable opinion of the
Placement Agent, it becomes necessary to amend or supplement the General Disclosure Package in
order to make the statements therein, in the light of the circumstances then prevailing, not
misleading, or to make the statements therein not conflict with the information contained or
incorporated by reference in the Registration Statement then on file and not superseded or
modified, or if it is necessary at any time to amend or supplement the General Disclosure
Package to comply with any law, the Company promptly will either (i) prepare, file with the
Commission (if required) and furnish to the Placement Agent and any dealers an appropriate
amendment or supplement to the General Disclosure Package or (ii) prepare and file with the
Commission an appropriate filing under the Exchange Act which shall be incorporated by reference
in the General Disclosure Package so that the General Disclosure Package as so amended or
supplemented will not, in the light of the circumstances then prevailing, be misleading or
conflict with the Registration Statement then on file, or so that the General Disclosure Package
will comply with law.
(e) If at any time following issuance of an Issuer Free Writing Prospectus there occurred
or occurs an event or development as a result of which such Issuer Free Writing Prospectus
conflicted or will conflict with the information contained in the Registration Statement,
Pricing Prospectus or Prospectus, including any document incorporated by reference therein and
any prospectus supplement deemed to be a part thereof and not superseded or modified or included
or would include an untrue statement of a material fact or omitted or would omit to state a
material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances prevailing at the subsequent time, not misleading,
the Company has promptly notified or will promptly notify the Placement Agent so that any use of
the Issuer Free Writing Prospectus may cease until it is amended or supplemented and has
promptly amended or will promptly amend or supplement, at its own expense, such Issuer Free
Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. The
foregoing sentence does not apply to
-20-
statements in or omissions from any Issuer Free Writing Prospectus in reliance upon, and in
conformity with, written information furnished to the Company by the Placement Agent
specifically for inclusion therein, which information the parties hereto agree is limited to the
Placement Agent’s Information (as defined in Section 17).
(f) To the extent not available on the Commission’s ▇▇▇▇▇ system or any successor system,
to furnish promptly to the Placement Agent and to counsel for the Placement Agent a signed copy
of the Registration Statement as originally filed with the Commission, and of each amendment
thereto filed with the Commission, including all consents and exhibits filed therewith.
(g) To the extent not available on the Commission’s ▇▇▇▇▇ system or any successor system,
to deliver promptly to the Placement Agent in New York City such number of the following
documents as the Placement Agent shall reasonably request: (i) conformed copies of the
Registration Statement as originally filed with the Commission (in each case excluding
exhibits), (ii) each Preliminary Prospectus, (iii) any Issuer Free Writing Prospectus, (iv) the
Prospectus (the delivery of the documents referred to in clauses (i), (ii), (iii) and (iv) of
this paragraph (g) to be made not later than 10:00 A.M., New York time, on the business
day following the execution and delivery of this Agreement), (v) conformed copies of any
amendment to the Registration Statement (excluding exhibits), (vi) any amendment or supplement
to the General Disclosure Package or the Prospectus (the delivery of the documents referred to
in clauses (v) and (vi) of this paragraph (g) to be made not later than 10:00 A.M., New
York City time, on the business day following the date of such amendment or supplement) and
(vii) any document incorporated by reference in the General Disclosure Package or the Prospectus
(excluding exhibits thereto) (the delivery of the documents referred to in clause (vi) of this
paragraph (g) to be made not later than 10:00 A.M., New York City time, on the business
day following the date of such document).
(h) To make generally available to its shareholders as soon as practicable, but in any
event not later than eighteen (18) months after the effective date of each Registration
Statement (as defined in Rule 158(c) under the Rules and Regulations), an earnings statement of
the Company and any Subsidiary (which need not be audited) complying with Section 11(a) of the
Securities Act and the Rules and Regulations (including, at the option of the Company, Rule
158); and to furnish to its shareholders as soon as practicable after the end of each fiscal
year an annual report (including a balance sheet and statements of income, shareholders’ equity
and cash flows of the Company and its consolidated subsidiaries certified by independent public
accountants) and as soon as possible after each of the first three fiscal quarters of each
fiscal year (beginning with the first fiscal quarter after the effective date of such
Registration Statement), consolidated summary financial information of the Company and its
subsidiaries for such quarter in reasonable detail.
(i) To take promptly from time to time such actions as the Placement Agent may reasonably
request to qualify the Units for offering and sale under the securities or Blue Sky laws of such
jurisdictions (domestic or foreign) as the Placement Agent may designate and to continue such
qualifications in effect, and to comply with such laws, for so long as required to permit the
offer and sale of Units in such jurisdictions; provided that the Company shall
-21-
not be obligated to qualify as foreign corporations in any jurisdiction in which they are
not so qualified or to file a general consent to service of process in any jurisdiction.
(j) To the extent not available on the Commission’s ▇▇▇▇▇ system or any successor system,
during the period of two (2) years from the date hereof, to deliver to the Placement Agent, (i)
as soon as they are available, copies of all reports or other communications furnished to
shareholders (other than reports, proxy statements and other information that is electronically
filed with the Commission via ▇▇▇▇▇ or any successor system), and (ii) as soon as they are
available, copies of any reports and financial statements furnished or filed with the Commission
or any national securities exchange or automatic quotation system on which the Company’s
securities are listed or quoted.
(k) That the Company will not, for a period of ninety (90) days from the date of the
Prospectus, (the “Lock-Up Period”) without the prior written consent of the Placement Agent,
directly or indirectly offer, sell, assign, transfer, pledge, contract to sell, or otherwise
dispose of, any shares of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock, other than: (i) the Company’s sale of the Units hereunder; (ii)
the issuance of restricted Common Stock or options to acquire Common Stock pursuant to the
Company’s employee benefit plans, qualified stock option plans or other employee compensation
plans as such plans are in existence on the date hereof and described in the Prospectus; and
(iii) the issuance of Common Stock pursuant to the valid exercises of options, warrants or
rights outstanding on the date hereof. The Company also agrees that during such period, the
Company will not file any registration statement, preliminary prospectus or prospectus, or any
amendment or supplement thereto, under the Securities Act for any such transaction or which
registers, or offers for sale, Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock, except for a registration statement on Form S-8 relating to
employee benefit plans. The Company hereby agrees that (i) if it issues an earnings release or
material news, or if a material event relating to the Company occurs, during the last seventeen
(17) days of the Lock-Up Period, or (ii) if prior to the expiration of the Lock-Up Period, the
Company announces that it will release earnings results during the sixteen (16)-day period
beginning on the last day of the Lock-Up Period, the restrictions imposed by this paragraph
(k) or the letter shall continue to apply until the expiration of the eighteen (18)-day
period beginning on the issuance of the earnings release or the occurrence of the material news
or material event.
(l) To supply the Placement Agent with copies of all correspondence to and from, and all
documents issued to and by, the Commission in connection with the registration of the Units
under the Securities Act or the Registration Statement, any Preliminary Prospectus or the
Prospectus, or any amendment or supplement thereto or document incorporated by reference
therein.
(m) Prior to the Closing Date, to furnish to the Placement Agent, as soon as they have been
prepared, copies of any unaudited interim consolidated financial statements of the Company for
any periods subsequent to the periods covered by the financial statements appearing in the
Registration Statement and the Prospectus.
-22-
(n) Prior to the Closing Date, not to issue any press release or other communication
directly or indirectly or hold any press conference with respect to the Company, its condition,
financial or otherwise, or earnings, business affairs or business prospects (except for routine
oral marketing communications in the ordinary course of business and consistent with the past
practices of the Company and of which the Placement Agent is notified), without the prior
written consent of the Placement Agent, unless in the judgment of the Company and its counsel,
and after notification to the Placement Agent, such press release or communication is required
by law.
(o) Until the Placement Agent shall have notified the Company of the completion of the
offering of the Units, that the Company will not, and will cause its affiliated purchasers (as
defined in Regulation M under the Exchange Act) not to, either alone or with one or more other
persons, bid for or purchase, for any account in which it or any of its affiliated purchasers
has a beneficial interest, any Units, or attempt to induce any person to purchase any Units; and
not to, and to cause its affiliated purchasers not to, make bids or purchase for the purpose of
creating actual, or apparent, active trading in or of raising the price of the
Units.
(p) Not to take any action prior to the Closing Date which would require the Prospectus to
be amended or supplemented pursuant to Section 5.
(q) To at all times comply in all material respects with all applicable provisions of the
▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act in effect from time to time.
(r) To apply the net proceeds from the sale of the Units as set forth in the Registration
Statement, the General Disclosure Package and the Prospectus under the heading “Use of
Proceeds.”
(s) To use its best efforts to effect, list and maintain, subject to notice of issuance,
the Common Stock on the NYSE Amex.
(t) To use its best efforts to assist the Placement Agent with any filings with FINRA and
obtaining clearance from FINRA as to the amount of compensation allowable or payable to the
Placement Agent.
(u) To use its best efforts to do and perform all things required to be done or performed
under this Agreement by the Company prior to the Closing Date and to satisfy all conditions
precedent to the delivery of the Units.
6. PAYMENT OF EXPENSES. The Company agrees to pay, or reimburse if paid by the Placement
Agent, whether or not the transactions contemplated hereby are consummated or this Agreement is
terminated: (a) the costs incident to the authorization, issuance, sale, preparation and delivery
of the Units to the Purchasers and any taxes payable in that connection; (b) the costs incident to
the Registration of the Units under the Securities Act; (c) the costs incident to the preparation,
printing and distribution of the Registration Statement, the Base Prospectus, any Preliminary
Prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus, any
amendments, supplements and exhibits thereto or any document incorporated by reference therein and
the costs of printing, reproducing and distributing any transaction
-23-
document by mail, telex or other means of communications; (d) the fees and expenses (including
related fees and expenses of counsel for the Placement Agent, if any) incurred in connection with
securing any required review by FINRA of the terms of the sale of the Units and any filings made
with FINRA; (e) any applicable listing, quotation or other fees; (f) the fees and expenses
(including related fees and expenses of counsel to the Placement Agent) of qualifying the Units
under the securities laws of the several jurisdictions as provided in Section 5(i) and of
preparing, printing and distributing wrappers, Blue Sky Memoranda and Legal Investment Surveys; (g)
the cost of preparing and printing stock certificates; (h) all fees and expenses of the registrar
and transfer agent of the Units; (i) the reasonable and documented fees, disbursements and expenses
of counsel to the Placement Agent not to exceed, along with any fees and expenses incurred in
connection with (d) above by counsel to the Placement Agent, $50,000 and (j) all other costs and
expenses incident to the offering of the Units or the performance of the obligations of the Company
under this Agreement (including, without limitation, the fees and expenses of the Company’s counsel
and the Company’s independent accountants and the travel and other reasonable documented expenses
incurred by Company personnel in connection with any “road show” including, without limitation, any
expenses advanced by the Placement Agent on the Company’s behalf (which will be promptly
reimbursed)); provided that, except to the extent otherwise provided in this Section 6 and
in Sections 8 and 10, the Placement Agent shall pay its own costs and expenses. In
no event will the total amount of compensation paid to the Placement Agent and other securities
brokers and dealers upon completion of this Offering exceed 8.0% of the gross proceeds of the
Offering.
7. CONDITIONS TO THE OBLIGATIONS OF THE PLACEMENT AGENT AND THE PURCHASERS, AND THE SALE OF
THE UNITS. The respective obligations of the Placement Agent hereunder and the Purchasers under
the Subscription Agreements, and the Closing of the sale of the Units, are subject to the accuracy,
when made and as of the Applicable Time and on the Closing Date, of the representations and
warranties of the Company contained herein, to the accuracy of the statements of the Company made
in any certificates pursuant to the provisions hereof, to the performance by the Company of its
obligations hereunder, and to each of the following additional terms and conditions:
(a) No stop order suspending the effectiveness of the Registration Statement or any part
thereof, preventing or suspending the use of any Base Prospectus, any Preliminary Prospectus,
the Prospectus or any Permitted Free Writing Prospectus or any part thereof shall have been
issued and no proceedings for that purpose or pursuant to Section 8A under the Securities Act
shall have been initiated or threatened by the Commission, and all requests for additional
information on the part of the Commission (to be included or incorporated by reference in the
Registration Statement or the Prospectus or otherwise) shall have been complied with to the
reasonable satisfaction of the Placement Agent; the Rule 462(b) Registration Statement, if any,
each Issuer Free Writing Prospectus, if any, and the Prospectus shall have been filed with the
Commission within the applicable time period prescribed for such filing by, and in compliance
with, the Rules and Regulations and in accordance with Section 5(a). and the Rule 462(b)
Registration Statement, if any, shall have become effective immediately upon its filing with the
Commission; and FINRA shall have raised no objection to the fairness and reasonableness of the
terms of this Agreement or the transactions contemplated hereby.
-24-
(b) The Placement Agent shall not have discovered and disclosed to the Company on or prior
to the Closing Date that the Registration Statement or any amendment or supplement thereto
contains an untrue statement of a fact which, in the opinion of counsel for the Placement Agent,
is material or omits to state any fact which, in the opinion of such counsel, is material and is
required to be stated therein or is necessary to make the statements therein not misleading, or
that the General Disclosure Package, any Issuer Free Writing Prospectus or the Prospectus or any
amendment or supplement thereto contains an untrue statement of fact which, in the opinion of
such counsel, is material or omits to state any fact which, in the opinion of such counsel, is
material and is necessary in order to make the statements, in the light of the circumstances in
which they were made, not misleading.
(c) All corporate proceedings and other legal matters incident to the authorization, form
and validity of each of this Agreement, the Subscription Agreements, the Units, the Registration
Statement, the General Disclosure Package, each Issuer Free Writing Prospectus, if any, and the
Prospectus and all other legal matters relating to this Agreement and the transactions
contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the
Placement Agent, and the Company shall have furnished to such counsel all documents and
information that they may reasonably request to enable them to pass upon such matters.
(d) ▇▇▇▇▇ ▇▇▇▇▇▇ LLP shall have furnished to the Placement Agent, such counsel’s written
opinion and negative assurances statement, as counsel to the Company, addressed to the Placement
Agent and dated the Closing Date, in the form and substance reasonably satisfactory to the
Placement Agent.
(e) The Placement Agent shall have received from Ernst & Young LLP, a letter, addressed to
the Placement Agent, executed and dated on the Closing Date, in form and substance satisfactory
to the Placement Agent (i) confirming that they are an independent registered accounting firm
with respect to the Company and any Subsidiary within the meaning of the Securities Act and the
Rules and Regulations and PCAOB and (ii) stating the conclusions and findings of such firm, of
the type ordinarily included in accountants’ “comfort letters” to underwriters, with respect to
the financial statements and certain financial information contained or incorporated by
reference in the Registration Statement, the General Disclosure Package and the Prospectus.
(f) The Company shall have furnished to the Placement Agent a certificate, dated the
Closing Date, of its Chief Executive Officer, its President or a Vice President and its Chief
Financial Officer stating that (i) such officers have carefully examined the Registration
Statement, the General Disclosure Package, any Permitted Free Writing Prospectus and the
Prospectus and, in their opinion, the Registration Statement and each amendment thereto, at the
Applicable Time and as of the date of this Agreement and as of the Closing Date did not include
any untrue statement of a material fact and did not omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, and the General
Disclosure Package, as of the Applicable Time and as of the Closing Date, any Permitted Free
Writing Prospectus as of its date and as of the Closing Date, the Prospectus and each amendment
or supplement thereto, as of the respective date thereof and as of the Closing Date, did not
include any untrue statement of a material fact and did not omit to state
-25-
a material fact necessary in order to make the statements therein, in the light of the
circumstances in which they were made, not misleading, (ii) since the effective date of the
Initial Registration Statement, no event has occurred which should have been set forth in a
supplement or amendment to the Registration Statement, the General Disclosure Package or the
Prospectus, (iii) to the best of their knowledge after reasonable investigation, as of the
Closing Date, the representations and warranties of the Company in this Agreement are true and
correct and the Company has complied with all agreements and satisfied all conditions on its
part to be performed or satisfied hereunder at or prior to the Closing Date, and (iv) there has
not been, subsequent to the date of the most recent audited financial statements included or
incorporated by reference in the General Disclosure Package, any material adverse change in the
financial position or results of operations of the Company or any Subsidiary, or any change or
development that, singularly or in the aggregate, would involve a material adverse change or a
prospective material adverse change, in or affecting the condition (financial or otherwise),
results of operations, business, assets or prospects of the Company or any Subsidiary, except as
set forth in the Prospectus.
(g) Since the date of the latest audited financial statements included in the General
Disclosure Package or incorporated by reference in the General Disclosure Package as of the date
hereof, (i) neither the Company nor any Subsidiary shall have sustained any loss or interference
with its business from fire, explosion, flood or other calamity, whether or not covered by
insurance, or from any labor dispute or court or governmental action, order or decree, otherwise
than as set forth in the General Disclosure Package, and (ii) there shall not have been any
change in the capital stock or long-term debt of the Company or any Subsidiary, or any change,
or any development involving a prospective change, in or affecting the business, management,
financial position, stockholders’ equity or results of operations of the Company, otherwise than
as set forth in the General Disclosure Package, the effect of which, in any such case described
in clause (i) or (ii) of this paragraph (g) is, in the judgment of the Placement Agent,
so material and adverse as to make it impracticable or inadvisable to proceed with the sale or
delivery of the Units on the terms and in the manner contemplated in the General Disclosure
Package.
(h) No action shall have been taken and no law, statute, rule, regulation or order shall
have been enacted, adopted or issued by any governmental agency or body which would prevent the
issuance or sale of the Units or materially and adversely affect or potentially materially and
adversely affect the business or operations of the Company or any Subsidiary; and no injunction,
restraining order or order of any other nature by any federal or state court of competent
jurisdiction shall have been issued which would prevent the issuance or sale of the Units or
materially and adversely affect or potentially materially and adversely affect the business or
operations of the Company or any Subsidiary.
(i) Subsequent to the execution and delivery of this Agreement there shall not have
occurred any of the following: (i) trading in securities generally on the New York Stock
Exchange, NYSE Amex or the Nasdaq Stock Market or in the over-the-counter market, or trading in
any securities of the Company on any exchange or in the over-the-counter market, shall have been
suspended or materially limited, or minimum or maximum prices or maximum range for prices shall
have been established on any such exchange or such market by the Commission, by such exchange or
market or by any other regulatory body or
-26-
governmental authority having jurisdiction, (ii) a banking moratorium shall have been
declared by Federal or state authorities or a material disruption has occurred in commercial
banking or securities settlement or clearance services in the United States, (iii) the United
States shall have become engaged in hostilities, or the subject of an act of terrorism, or there
shall have been an outbreak of or escalation in hostilities involving the United States, or
there shall have been a declaration of a national emergency or war by the United States or (iv)
there shall have occurred such a material adverse change in general economic, political or
financial conditions (or the effect of international conditions on the financial markets in the
United States shall be such) as to make it, in the judgment of the Placement Agent,
impracticable or inadvisable to proceed with the sale or delivery of the Units on the terms and
in the manner contemplated in the General Disclosure Package and the Prospectus.
(j) The NYSE Amex shall have approved the Common Stock for inclusion therein, subject only
to official notice of issuance.
(k) The Company shall have entered into Subscription Agreements with each of the Purchasers
and such agreements shall be in full force and effect.
(l) FINRA shall have raised no objection as to the amount of compensation allowable or
payable to the Placement Agent as described in the Pricing Prospectus.
(m) Prior to the Closing Date, the Company shall have furnished to the Placement Agent such
further information, opinions, certificates, letters or documents as the Placement Agent shall
have reasonably requested.
All opinions, letters, evidence and certificates mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Placement Agent.
8. INDEMNIFICATION AND CONTRIBUTION.
(a) The Company shall indemnify and hold harmless the Placement Agent, its affiliates and
each of its and their respective directors, officers, members, employees, representatives and
agents and its affiliates, and each of its and their respective directors, officers, members,
employees, representatives and agents and each person, if any, who controls the Placement Agent
within the meaning of Section 15 of the Securities Act of or Section 20 of the Exchange Act
(collectively the “Placement Agent Indemnified Parties,” and each a “Placement Agent Indemnified
Party”) against any loss, claim, damage, expense or liability whatsoever (or any action,
investigation or proceeding in respect thereof), joint or several, to which such Placement Agent
Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such
loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is
based upon (A) any untrue statement or alleged untrue statement of a material fact contained in
any Preliminary Prospectus, any Issuer Free Writing Prospectus, any ”issuer information” filed
or required to be filed pursuant to Rule 433(d) under the Rules and Regulations, any
Registration Statement or the Prospectus, or in any amendment or supplement thereto or document
incorporated by reference therein, (B) the omission or alleged omission to state in any
Preliminary
-27-
Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required
to be filed pursuant to Rule 433(d) under the Rules and Regulations, any Registration Statement
or the Prospectus, or in any amendment or supplement thereto or document incorporated by
reference therein, a material fact required to be stated therein or necessary to make the
statements therein not misleading, or (C) any breach of the representations and warranties of
the Company contained herein or failure of the Company to perform its obligations hereunder or
pursuant to any law, any act or failure to act, or any alleged act or failure to act, by the
Placement Agent in connection with, or relating in any manner to, the Units or the Offering, and
which is included as part of or referred to in any loss, claim, damage, expense, liability,
action, investigation or proceeding arising out of or based upon matters covered by subclause
(A), (B) or (C) above of this Section 8(a) (provided that the Company shall not be
liable in the case of any matter covered by this subclause (C) to the extent that it is
determined in a final judgment by a court of competent jurisdiction that such loss, claim,
damage, expense or liability resulted directly from any such act or failure to act undertaken or
omitted to be taken by the Placement Agent through its gross negligence or willful misconduct),
and shall reimburse the Placement Agent Indemnified Party promptly upon demand for any legal
fees or other expenses reasonably incurred by that Placement Agent Indemnified Party in
connection with investigating, or preparing to defend, or defending against, or appearing as a
third party witness in respect of, or otherwise incurred in connection with, any such loss,
claim, damage, expense, liability, action, investigation or proceeding, as such fees and
expenses are incurred; provided, however, that the Company shall not be liable in any such case
to the extent that any such loss, claim, damage, expense or liability arises out of or is based
upon an untrue statement or alleged untrue statement in, or omission or alleged omission from
any Preliminary Prospectus, any Registration Statement or the Prospectus, or any such amendment
or supplement thereto, or any Issuer Free Writing Prospectus made in reliance upon and in
conformity with written information furnished to the Company by the Placement Agent specifically
for use therein, which information the parties hereto agree is limited to the Placement Agent’s
Information (as defined in Section 17). This indemnity agreement is not exclusive and
will be in addition to any liability, which the Company might otherwise have and shall not limit
any rights or remedies which may otherwise be available at law or in equity to the Placement
Agent Indemnified Party.
(b) The Placement Agent shall indemnify and hold harmless the Company and its directors,
its officers who signed the Registration Statement and each person, if any, who controls the
Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act
(collectively the “Company Indemnified Parties” and each a “Company Indemnified Party”) against
any loss, claim, damage, expense or liability whatsoever (or any action, investigation or
proceeding in respect thereof), joint or several, to which such Company Indemnified Party may
become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage,
expense, liability, action, investigation or proceeding arises out of or is based upon (i) any
untrue statement or alleged untrue statement of a material fact contained in any Preliminary
Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be
filed pursuant to Rule 433(d) under the Rules and Regulations, any Registration Statement or the
Prospectus, or in any amendment or supplement thereto, or (ii) the omission or alleged omission
to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer
information” filed or required to
-28-
be filed pursuant to Rule 433(d) under the Rules and Regulations, any Registration
Statement or the Prospectus, or in any amendment or supplement thereto, a material fact required
to be stated therein or necessary to make the statements therein not misleading, but in each
case only to the extent that the untrue statement or alleged untrue statement or omission or
alleged omission was made in reliance upon and in conformity with written information furnished
to the Company by the Placement Agent specifically for use therein, which information the
parties hereto agree is limited to the Placement Agent’s Information as defined in Section
17 and shall reimburse the Company for any legal or other expenses reasonably incurred by
such party in connection with investigating or preparing to defend or defending against or
appearing as third party witness in connection with any such loss, claim, damage, liability,
action, investigation or proceeding, as such fees and expenses are incurred. Notwithstanding
the provisions of this Section 8(b) in no event shall any indemnity by the Placement
Agent under this Section 8(b) exceed the total compensation received by the Placement
Agent in accordance with Section 2.5.
(c) Promptly after receipt by an indemnified party under this Section 8 of notice
of the commencement of any action, the indemnified party shall, if a claim in respect thereof is
to be made against an indemnifying party under this Section 8 notify such indemnifying
party in writing of the commencement of that action; provided, however, that the failure to
notify the indemnifying party shall not relieve it from any liability which it may have under
this Section 8 except to the extent it has been materially prejudiced by such failure;
and, provided, further, that the failure to notify an indemnifying party shall not relieve it
from any liability which it may have to an indemnified party otherwise than under this
Section 8. If any such action shall be brought against an indemnified party, and it
shall notify the indemnifying party thereof, the indemnifying party shall be entitled to
participate therein and, to the extent that it wishes, jointly with any other similarly notified
indemnifying party, to assume the defense of such action with counsel reasonably satisfactory to
the indemnified party (which counsel shall not, except with the written consent of the
indemnified party, be counsel to the indemnifying party). After notice from the indemnifying
party to the indemnified party of its election to assume the defense of such action, except as
provided herein, the indemnifying party shall not be liable to the indemnified party under
Section 8 for any legal or other expenses subsequently incurred by the indemnified party
in connection with the defense of such action other than reasonable costs of investigation;
provided, however, that any indemnified party shall have the right to employ separate counsel in
any such action and to participate in the defense of such action but the fees and expenses of
such counsel (other than reasonable costs of investigation) shall be at the expense of such
indemnified party unless (i) the employment thereof has been specifically authorized in writing
by the Company in the case of a claim for indemnification under Section 8(a) or
Section 2.6 or the Placement Agent in the case of a claim for indemnification under
Section 8(b). (ii) such indemnified party shall have been advised by its counsel that
there may be one or more legal defenses available to it which are different from or additional
to those available to the indemnifying party, or (iii) the indemnifying party has failed to
assume the defense of such action and employ counsel reasonably satisfactory to the indemnified
party within a reasonable period of time after notice of the commencement of the action or the
indemnifying party does not diligently defend the action after assumption of the defense, in
which case, if such indemnified party notifies the indemnifying party in writing that it elects
to employ separate counsel at the expense of the indemnifying party, the indemnifying
-29-
party shall not have the right to assume the defense of (or, in the case of a failure to
diligently defend the action after assumption of the defense, to continue to defend) such action
on behalf of such indemnified party and the indemnifying party shall be responsible for legal or
other expenses subsequently incurred by such indemnified party in connection with the defense of
such action; provided, however, that the indemnifying party shall not, in connection with any
one such action or separate but substantially similar or related actions in the same
jurisdiction arising out of the same general allegations or circumstances, be liable for the
reasonable fees and expenses of more than one separate firm of attorneys at any time for all
such indemnified parties (in addition to any local counsel), which firm shall be designated in
writing by the Placement Agent if the indemnified parties under this Section 8 consist
of any Placement Agent Indemnified Party or by the Company if the indemnified parties under this
Section 8 consist of any Company Indemnified Parties. Subject to this Section
8(c), the amount payable by an indemnifying party under Section 8 shall include, but
not be limited to, (x) reasonable legal fees and expenses of counsel to the indemnified party
and any other expenses in investigating, or preparing to defend or defending against, or
appearing as a third party witness in respect of, or otherwise incurred in connection with, any
action, investigation, proceeding or claim, and (y) all amounts paid in settlement of any of the
foregoing. No indemnifying party shall, without the prior written consent of the indemnified
parties, settle or compromise or consent to the entry of judgment with respect to any pending or
threatened action or any claim whatsoever, in respect of which indemnification or contribution
could be sought under this Section 8 (whether or not the indemnified parties are actual
or potential parties thereto), unless such settlement, compromise or consent (i) includes an
unconditional release of each indemnified party in form and substance reasonably satisfactory to
such indemnified party from all liability arising out of such action or claim and (ii) does not
include a statement as to or an admission of fault, culpability or a failure to act by or on
behalf of any indemnified party. Subject to the provisions of the following sentence, no
indemnifying party shall be liable for settlement of any pending or threatened action or any
claim whatsoever that is effected without its written consent (which consent shall not be
unreasonably withheld or delayed), but if settled with its written consent, if its consent has
been unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such
matter, the indemnifying party agrees to indemnify and hold harmless any indemnified party from
and against any loss or liability by reason of such settlement or judgment. In addition, if at
any time an indemnified party shall have requested that an indemnifying party reimburse the
indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall
be liable for any settlement of the nature contemplated herein effected without its written
consent if (i) such settlement is entered into more than forty-five (45) days after receipt by
such indemnifying party of the request for reimbursement, (ii) such indemnifying party shall
have received notice of the terms of such settlement at least thirty (30) days prior to such
settlement being entered into and (iii) such indemnifying party shall not have reimbursed such
indemnified party in accordance with such request prior to the date of such settlement.
(d) If the indemnification provided for in this Section 8 is unavailable or
insufficient to hold harmless an indemnified party under Section 8(a) or Section
8(b), then each indemnifying party shall, in lieu of indemnifying such indemnified party,
contribute to the amount paid, payable or otherwise incurred by such indemnified party as a
result of such loss, claim, damage, expense or liability (or any action, investigation or
proceeding in respect
-30-
thereof), as incurred, (i) in such proportion as shall be appropriate to reflect the
relative benefits received by the Company on the one hand and the Placement Agent on the other
hand from the offering of the Units, or (ii) if the allocation provided by clause (i) of this
Section 8(d) is not permitted by applicable law, in such proportion as is appropriate to
reflect not only the relative benefits referred to in clause (i) of this Section 8(d)
but also the relative fault of the Company on the one hand and the Placement Agent on the other
with respect to the statements, omissions, acts or failures to act which resulted in such loss,
claim, damage, expense or liability (or any action, investigation or proceeding in respect
thereof) as well as any other relevant equitable considerations. The relative benefits received
by the Company on the one hand and the Placement Agent on the other with respect to such
offering shall be deemed to be in the same proportion as the total net proceeds from the
offering of the Units purchased under this Agreement (before deducting expenses) received by the
Company bear to the total Placement Fee received by the Placement Agent in connection with the
Offering, in each case as set forth in the table on the cover page of the Prospectus. The
relative fault of the Company on the one hand and the Placement Agent on the other shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement
of a material fact or the omission or alleged omission to state a material fact relates to
information supplied by the Company on the one hand or the Placement Agent on the other, the
intent of the parties and their relative knowledge, access to information and opportunity to
correct or prevent such untrue statement, omission, act or failure to act; provided that the
parties hereto agree that the written information furnished to the Company by the Placement
Agent for use in any Preliminary Prospectus, any Registration Statement or the Prospectus, or in
any amendment or supplement thereto, consists solely of the Placement Agent’s Information as
defined in Section 17. The Company and the Placement Agent agree that it would not be
just and equitable if contributions pursuant to this Section 8(d) were to be determined
by pro rata allocation or by any other method of allocation that does not take into account the
equitable considerations referred to herein. The amount paid or payable by an indemnified party
as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding
referred to above in this Section 8(d) shall be deemed to include, for purposes of this
Section 8(d). any legal or other expenses reasonably incurred by such indemnified party
in connection with investigating, preparing to defend or defending against or appearing as a
third party witness in respect of, or otherwise incurred in connection with, any such loss,
claim, damage, expense, liability, action, investigation or proceeding. Notwithstanding the
provisions of this Section 8(d), the Placement Agent shall not be required to contribute
any amount in excess of the total compensation received by the Placement Agent in accordance
with Section 2.5 less the amount of any damages which the Placement Agent has otherwise
paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or
alleged omission, act or alleged act or failure to act or alleged failure to act. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation.
9. TERMINATION. The obligations of the Placement Agent and the Purchasers hereunder and under
the Subscription Agreements may be terminated by the Placement Agent, in its absolute discretion by
notice given to the Company prior to delivery of and payment for the Units if, prior to that time,
any of the events described in Section 7 have occurred or if the
-31-
Purchasers shall decline to purchase the Units for any reason permitted under this Agreement
or the Subscription Agreements.
10. REIMBURSEMENT OF PLACEMENT AGENT’S EXPENSES. Notwithstanding anything to the contrary in
this Agreement, if (a) this Agreement shall have been terminated pursuant to Section 9, (b)
the Company shall fail to tender the Units for delivery to the Purchasers for any reason not
permitted under this Agreement, (c) the Purchasers shall decline to purchase the Units for any
reason permitted under this Agreement or (d) the sale of the Units is not consummated because any
condition to the obligations of the Purchasers or the Placement Agent set forth herein is not
satisfied or because of the refusal, inability or failure on the part of the Company to perform any
agreement herein or to satisfy any condition or to comply with the provisions hereof, then in
addition to the payment of amounts in accordance with Section 6 the Company shall reimburse
the Placement Agent for the reasonable documented and accountable fees and expenses of the
Placement Agent’s counsel and for such other out-of-pocket expenses as shall have been reasonably
incurred by them in connection with this Agreement and the proposed purchase of the Units, and upon
demand the Company shall pay the full amount thereof to the Placement Agent.
11. ABSENCE OF FIDUCIARY RELATIONSHIP. The Company acknowledges and agrees that:
(a) the Placement Agent’s responsibility to the Company is solely contractual in nature,
the Placement Agent has been retained solely to act as Placement Agent in connection with the
Offering and no fiduciary, advisory or agency relationship between the Company and the Placement
Agent has been created in respect of any of the transactions contemplated by this Agreement,
irrespective of whether the Placement Agent has advised or is advising the Company on other
matters;
(b) the price of the Units set forth in this Agreement was established by the Company
following discussions and arms-length negotiations with the Placement Agent, and the Company is
capable of evaluating and understanding, and understands and accepts, the terms, risks and
conditions of the transactions contemplated by this Agreement;
(c) it has been advised that the Placement Agent and its affiliates are engaged in a broad
range of transactions which may involve interests that differ from those of the Company and that
the Placement Agent has no obligation to disclose such interests and transactions to the Company
by virtue of any fiduciary, advisory or agency relationship; and
(d) it waives, to the fullest extent permitted by law, any claims it may have against the
Placement Agent for breach of fiduciary duty or alleged breach of fiduciary duty and agrees that
the Placement Agent shall have no liability (whether direct or indirect) to the Company in
respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on
behalf of or in right of the Company, including stockholders, employees or creditors of the
Company.
12. SUCCESSORS; PERSONS ENTITLED TO BENEFIT OF AGREEMENT. This Agreement shall inure to the
benefit of and be binding upon the Placement Agent, the Company,
-32-
and their respective successors and assigns. This Agreement shall also inure to the benefit
of the Purchasers, and each of their respective successors and assigns, which shall be third party
beneficiaries hereof. Nothing expressed or mentioned in this Agreement is intended or shall be
construed to give any person, other than the persons mentioned in the preceding sentences, any
legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions
herein contained, this Agreement and all conditions and provisions hereof being intended to be and
being for the sole and exclusive benefit of such persons and for the benefit of no other person;
except that the representations, warranties, covenants, agreements and indemnities of the Company
contained in this Agreement shall also be for the benefit of the Placement Agent Indemnified
Parties and the indemnities of the Placement Agent shall be for the benefit of the Company
Indemnified Parties. It is understood that the Placement Agent’s responsibility to the Company is
solely contractual in nature and the Placement Agent does not owe the Company, or any other party,
any fiduciary duty as a result of this Agreement.
13. SURVIVAL OF INDEMNITIES, REPRESENTATIONS, WARRANTIES, ETC. The respective indemnities,
covenants, agreements, representations, warranties and other statements of the Company and the
Placement Agent, as set forth in this Agreement or made by them respectively, pursuant to this
Agreement, shall remain in full force and effect, regardless of any investigation made by or on
behalf of the Placement Agent, the Company, the Purchasers or any person controlling any of them
and shall survive delivery of and payment for the Units. Notwithstanding any termination of this
Agreement, including without limitation any termination pursuant to Sections 9 or
10, the indemnity and contribution agreements contained in Section 8 and the
covenants, representations, warranties set forth in this Agreement shall not terminate and shall
remain in full force and effect at all times.
14. NOTICES. All statements, requests, notices and agreements hereunder shall be in writing,
and:
(a) if to the Placement Agent, shall be delivered or sent by mail, telex, facsimile
transmission or overnight courier to ▇▇▇▇ Capital Partners, LLC, ▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇
▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, Attention: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, Fax: (▇▇▇) ▇▇▇-▇▇▇▇, with a copy (which
shall not constitute notice) to: ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ PC, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇,
▇▇ ▇▇▇▇▇, Attention: ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, Esq., Fax (▇▇▇-▇▇▇-▇▇▇▇); and
(b) if to the Company, shall be delivered or sent by mail, telex, facsimile transmission or
overnight courier to ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ West, Building 18, Suite 400, Blue ▇▇▇▇, Pennsylvania
19422, Attention: Chief Executive Officer, Fax: (▇▇▇) ▇▇▇-▇▇▇▇ with a copy (which shall not
constitute notice) to: ▇▇▇▇▇ ▇▇▇▇▇▇ LLP, ▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, Attention ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, Esq., Fax: (▇▇▇) ▇▇▇-▇▇▇▇.
Any such statements, requests, notices or agreements shall take effect at the time of receipt
thereof, except that any such statement, request, notice or agreement delivered or sent by email
shall take effect at the time of confirmation of receipt thereof by the recipient thereof.
15. DEFINITION OF CERTAIN TERMS. For purposes of this Agreement, “business day” means any day
on which the New York Stock Exchange, Inc. is open for trading.
-33-
16. GOVERNING LAW, AGENT FOR SERVICE AND JURISDICTION. This Agreement shall be governed by
and construed in accordance with the laws of the State of New York, including without limitation
Section 5-1401 of the New York General Obligations Law. No legal proceeding may be commenced,
prosecuted or continued in any court other than the courts of the State of New York located in the
City and County of New York or in the United States District Court for the Southern District of New
York, which courts shall have jurisdiction over the adjudication of such matters, and the Company
and the Placement Agent each hereby consent to the jurisdiction of such courts and personal service
with respect thereto. The Company and the Placement Agent each hereby consent to personal
jurisdiction, service and venue in any court in which any legal proceeding arising out of or in any
way relating to this Agreement is brought by any third party against the Company or the Placement
Agent. The Company and the Placement Agent each hereby waive all right to trial by jury in any
legal proceeding (whether based upon contract, tort or otherwise) in any way arising out of or
relating to this Agreement. The Company agrees that a final judgment in any such legal proceeding
brought in any such court shall be conclusive and binding upon the Company and the Placement Agent
and may be enforced in any other courts in the jurisdiction of which the Company is or may be
subject, by suit upon such judgment.
17. PLACEMENT AGENT’S INFORMATION. The parties hereto acknowledge and agree that, for all
purposes of this Agreement, the Placement Agent’s Information consists solely of the following
information in the Prospectus: (i) the last paragraph on the front cover page concerning the terms
of the offering by the Placement Agent; and (ii) the statements concerning the Placement Agent
contained in the first paragraph under the heading ”Plan of Distribution.”
18. PARTIAL UNENFORCEABILITY. The invalidity or unenforceability of any section, paragraph,
clause or provision of this Agreement shall not affect the validity or enforceability of any other
section, paragraph, clause or provision hereof. If any section, paragraph, clause or provision of
this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed
to be made such minor changes (and only such minor changes) as are necessary to make it valid and
enforceable.
19. GENERAL. This Agreement constitutes the entire agreement of the parties to this Agreement
and supersedes all prior written or oral and all contemporaneous oral agreements, understandings
and negotiations with respect to the subject matter hereof. In this Agreement, the masculine,
feminine and neuter genders and the singular and the plural include one another. The Section
headings in this Agreement are for the convenience of the parties only and will not affect the
construction or interpretation of this Agreement. This Agreement may be amended or modified, and
the observance of any term of this Agreement may be waived, only by a writing signed by the Company
and the Placement Agent.
20. COUNTERPARTS. This Agreement may be signed in any number of counterparts, each of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument and such signatures may be delivered by facsimile.
-34-
If the foregoing is in accordance with your understanding of the agreement between the Company
and the Placement Agent, kindly indicate your acceptance in the space provided for that purpose
below.
| Very truly yours, INOVIO PHARMACEUTICALS, INC. |
||||
| By: | /s/ J. ▇▇▇▇▇▇ ▇▇▇ | |||
| Name: | J. ▇▇▇▇▇▇ ▇▇▇ | |||
| Title: | President & Chief Executive Officer | |||
| Accepted as of the date first above written: | ||||
| ▇▇▇▇ CAPITAL MARKETS, LLC | ||||
By:
|
/s/ ▇▇▇▇▇ Gurewits
|
|||
| Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ | ||||
| Title: Head of Equity Capital Markets | ||||
-35-
SCHEDULE A
General Use Free Writing Prospectuses
None
EXHIBIT A
Form of Subscription Agreement
EXHIBIT B
Form of Warrant
C-1